Replies to post #28968 on Marker Therapeutics Inc (MRKR)

[Phantom Lord]

To be honest the writing was on the wall for the TPIV200 trial in ovarian. The combo trial with durvalumab was stopped last year because TPIV200 did not add any clinical benefit beyond what durvalumab offered alone. It's unfortunate but lucky for us the future of Marker does not lie in the hands of the vaccines. It's MultiTAA from here on out. If the vaccines produce some results in the DoD funded trials than that will be icing on the cake. The shutting down of the company sponsored TPIV200 trial in ovarian should be a blessing in disguise as it should lower the cash burn rate.